Turtle; Cameron J.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Turtle; Cameron J..The latest application filed is for "biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods".

Company Profile

3.5.7

Turtle; Cameron J. - Seattle WA
Turtle; Cameron J - Seattle WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Biomarkers and uses thereof for selecting immunotherapy intervention Grant 11,397,183 - Liles , et al. July 26, 2	2022-07-26
Biomarkers, Uses Thereof For Selecting Immunotherapy Intervention, And Immunotherapy Methods App 20210223248 - TURTLE; Cameron J. ; et al.	2021-07-22
Identification of CD8.sup.+ T cells that are CD161.sup.hi and/or IL18R(.alpha.).sup.hi and have rapid drug efflux capacity Grant 10,653,756 - Turtle , et al.	2020-05-19
Methods For The Treatment Of B Cell Malignancies Using Adoptive Cell Therapy App 20200016199 - TURTLE; Cameron J. ; et al.	2020-01-16
Biomarkers And Uses Thereof For Selecting Immunotherapy Intervention App 20190361026 - LILES; W. Conrad ; et al.	2019-11-28
Methods And Compositions Related To Toxicity Associated With Cell Therapy App 20190277858 - LI; He ; et al.	2019-09-12
Identification Of Cd8+ T Cells That Are Cd161hi And/or Il18r(alpha)hi And Have Rapid Drug Efflux Capacity App 20180243386 - Turtle; Cameron J. ; et al.	2018-08-30
Identification of CD8.sup.+ T cells that are CD161.sup.hi and/or IL18R.alpha..sup.hi and have rapid drug efflux capacity Grant 9,931,384 - Turtle , et al. April 3, 2	2018-04-03
Identification Of Cd8+ T Cells That Are Cd161hi And/or Il18r(alpha)hi And Have Rapid Drug Efflux Capacity App 20160045580 - Turtle; Cameron J. ; et al.	2016-02-18
Identifcation of CD8.sup.+ T cells that are CD161.sup.hi and/or IL18R.alpha..sup.hi and have rapid drug efflux capacity Grant 9,090,875 - Turtle , et al. July 28, 2	2015-07-28
Identification Of Cd8+ T Cells That Are Cd161hi And/or Il18r (alpha) Hi And Have Rapid Drug Efflux Capacity App 20110059012 - Turtle; Cameron J ; et al.	2011-03-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.